BioMarin Pharmaceutical (BMRN), What Is Behind The Fresh Attention?

BioMarin Pharmaceutical (BMRN) is back in focus after a settlement and license agreement with Ascendis Pharma over YUVIWEL turned a direct achondroplasia competitor into a potential royalty stream for BioMarin.

At a share price of US$66.53, BioMarin Pharmaceutical has enjoyed a 30 day share price return of 11.05% and a 90 day share price return of 17.19%. The 1 year total shareholder return of 15.16% contrasts with a 3 year total shareholder return that has declined 26.23% and a 5 year total shareholder return that has declined 14.68%, which hints that recent momentum around deals like the Ascendis settlement comes after a tougher multi year period for long term holders.

Seize this chance to reassess BioMarin Pharmaceutical in the context of other potential rebound stories by scanning our hand picked 19 high quality undiscovered gems that currently sit off most investors' radar.

For BioMarin Pharmaceutical, the recent jump after the Ascendis deal could reflect investors re-rating the underlying rare disease platform rather than just cheering a legal win. Does that optimism line up with what the current valuation suggests?

Most Popular Narrative: 46.3% Undervalued

At a last close of $66.53, the most followed narrative on BioMarin Pharmaceutical points to a fair value of $124, which implies a large gap that hinges on how investors view its rare disease portfolio and pipeline.

While analyst consensus expects strong revenue growth from VOXZOGO's global rollout and future hypochondroplasia launch, these projections may substantially understate the magnitude and duration of demand, accelerating diagnosis initiatives and high adherence among young children, combined with a complete lack of competition in the 0-4 age cohort and ongoing expansion into new countries, position VOXZOGO for an extended multi-year period of outsized sales growth and margin accretion as penetration deepens worldwide.

Read the complete narrative.

Want to see why this narrative leans so heavily on one product to justify that higher fair value? The entire case turns on ambitious revenue, margin, and earnings step ups that only line up if multiple moving parts break in BioMarin Pharmaceutical's favor over the next few years.

The narrative builds that $124 fair value using a discount rate of 8.01% and a set of aggressive forecasts for revenue growth, margin expansion, and future earnings scale. It assumes that current profit margins near 2% are a starting point for a much higher profitability profile, and that the existing rare disease portfolio plus late stage assets can support that shift over time. The gap between this view and the present share price reflects how differently the market and the narrative currently weigh those future outcomes.

Result: Fair Value of $124 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, BioMarin Pharmaceutical still carries key risks related to pricing pressure on rare disease drugs, as well as the possibility that concentrated pipeline bets like BMN 333 or BMN 401 disappoint.

Find out about the key risks to this BioMarin Pharmaceutical narrative.

Next Steps

Given the mix of optimism around BioMarin Pharmaceutical's pipeline and concerns about its risk profile, it makes sense to review the underlying data yourself and decide where you stand. If you want a concise snapshot of both sides of the story, start with these 3 key rewards and 4 important warning signs

Looking for more investment ideas beyond BioMarin Pharmaceutical?

Do not stop your research with BioMarin Pharmaceutical. The market is full of other opportunities that could fit your goals and risk comfort.

• Target potential mispricings by scanning companies that combine quality fundamentals with attractive valuations through our 47 high quality undervalued stocks.
• Strengthen your income focus by reviewing a curated set of companies offering higher yields and resilient payout histories with the 11 dividend fortresses.
• Prioritize resilience by checking companies that show robust balance sheets and solid fundamentals using the list of solid balance sheet and fundamentals (52 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com